News

Phase 3 prospective/retrospective study of MAFTest® in Lancet Oncology demonstrates the effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer

Inbiomotion SL today announced the publication of the results of the Phase 3 AZURE prospective/retrospective analysis using its proprietary single gene based MAFTest® in the November issue of Lancet Oncology

Read More about "Phase 3 prospective/retrospective study of MAFTest® in Lancet Oncology demonstrates the effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer"

”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital

The investment has been made through Caixa Innvierte BioMed II, a vehicle managed by Caixa Capital Risc, the venture capital arm of "la Caixa". The fund is driven by "la Caixa" and the Centro para el Desarrollo Tecnológico Industrial (Centre for Industrial Technological Development, CDTI) under the framework of the Innvierte Programme and has minority participation from the Institut Català de Finances.

Read More about "”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital"

IRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone

Physicians currently have no tools to help them detect which breast cancer patients will suffer metastasis to the bone, a process that occurs in 15-20% of cases. A study led by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) and published today in JNCI has uncovered a gene that allows breast cancer cells to invade bones and create new tumours, or to metastasize.

Read More about "IRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone"

Inbiomotion creates a world class Scientific Advisory Board chaired by Prof. Rob E. Coleman

Inbiomotion SL, a company focused on the development of biomarkers for the prediction of bone metastasis, today announced the creation of its Scientific Advisory Board with renowned experts in various disciplines, including bone metastatic disease, biomarker development, translational research and medical oncology.

Read More about "Inbiomotion creates a world class Scientific Advisory Board chaired by Prof. Rob E. Coleman"

Ysios Capital leads a € 2M Series A round of Inbiomotion

Ysios Capital, a leading Spanish life sciences venture capital firm, today announces that it has led the €2 million Series A financing of Inbiomotion SL, a spin-out company from the Growth Control and Cancer Metastasis group at the Institute for Research in Biomedicine (IRB Barcelona) and ICREA focused on the development of biomarkers for the prediction of bone metastasis from primary tumor biopsies. Additional investors participating in the round include Fundació Vila Casas and JVRisk Technologies.

Read More about "Ysios Capital leads a € 2M Series A round of Inbiomotion"